NRXS
Neuraxis, INC
NASDAQ · Healthcare · Biotechnology · US
$7.61
−0.26%Next report
Analyst consensus
- Next report date
- Nov 17, 2026
- EPS estimate
- -$0.21
- Revenue estimate
- $2.1M
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.19
- EPS estimate
- -$0.32
- Revenue actual
- $1.9M
- Revenue estimate
- $2.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -114.2%
- Revenue beats (12Q)
- 2
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.32 | -$0.19 | Beat 40.63% | $1.9M |
| May 12, 2026 | -$0.19 | -$0.18 | Beat 5.26% | $1.6M |
| Mar 19, 2026 | -$0.21 | -$0.17 | Beat 20.93% | $968.0K |
| Aug 12, 2025 | — | -$0.22 | — | $894.1K |
| Mar 20, 2025 | — | -$0.21 | — | $761.2K |
| Aug 9, 2024 | — | -$0.42 | — | $611.5K |
| May 20, 2024 | — | -$0.32 | — | $646.6K |
| Nov 20, 2023 | -$0.17 | -$1.06 | Miss -523.53% | $477.5K |
| Aug 18, 2023 | — | -$0.37 | — | $646.0K |
| Dec 31, 2022 | — | -$0.00 | — | $613.1K |
| Sep 30, 2022 | — | -$0.25 | — | $618.8K |
| Jun 30, 2022 | — | -$0.18 | — | $682.6K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 17, 2026